The already substantial collaboration between tech and medicine should be encouraged and financed post-pandemic to make conduct of clinical trials more convenient, efficient AND DEMOCRATIC.  More can be done at home using existing devices and equipment. Telemedicine should continue to be expanded and the efficiencies that have been achieved during the pandemic through telemedicine, remote monitoring, consent flexibility and other novel trial accommodations should continue.  The regulators need to be brought on board to ensure that these efficiencies are able to continue after things return to “normal”.  The effort is already well underway but needs continued financial, legal and political encouragement. Multidisciplinary approaches in all areas should be encouraged.